User: Guest  Login
Title:

Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.

Document type:
Article; Journal Article; Research Support, Non-U.S. Gov't
Author(s):
Malehmir, Mohsen; Pfister, Dominik; Gallage, Suchira; Szydlowska, Marta; Inverso, Donato; Kotsiliti, Elena; Leone, Valentina; Peiseler, Moritz; Surewaard, Bas G J; Rath, Dominik; Ali, Adnan; Wolf, Monika Julia; Drescher, Hannah; Healy, Marc E; Dauch, Daniel; Kroy, Daniela; Krenkel, Oliver; Kohlhepp, Marlene; Engleitner, Thomas; Olkus, Alexander; Sijmonsma, Tjeerd; Volz, Julia; Deppermann, Carsten; Stegner, David; Helbling, Patrick; Nombela-Arrieta, César; Rafiei, Anahita; Hinterleitner, Martina;...     »
Abstract:
Non-alcoholic fatty liver disease ranges from steatosis to non-alcoholic steatohepatitis (NASH), potentially progressing to cirrhosis and hepatocellular carcinoma (HCC). Here, we show that platelet number, platelet activation and platelet aggregation are increased in NASH but not in steatosis or insulin resistance. Antiplatelet therapy (APT; aspirin/clopidogrel, ticagrelor) but not nonsteroidal anti-inflammatory drug (NSAID) treatment with sulindac prevented NASH and subsequent HCC development....     »
Journal title abbreviation:
Nat Med
Year:
2019
Journal volume:
25
Journal issue:
4
Pages contribution:
641-655
Fulltext / DOI:
doi:10.1038/s41591-019-0379-5
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/30936549
Print-ISSN:
1078-8956
TUM Institution:
Professur für Translationale gastroenterologische Onkologie (Prof. Rad); Roman Herzog Comprehensive Cancer Center
 BibTeX